# A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

> **NCT06920043** · PHASE2 · RECRUITING · sponsor: **Boston Pharmaceuticals** · enrollment: 42 (estimated)

## Conditions studied

- Metabolic Dysfunction-Associated Steatohepatitis

## Interventions

- **DRUG:** Efimosfermin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06920043
- **Lead sponsor:** Boston Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-09
- **Primary completion:** 2027-11
- **Final completion:** 2027-12
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06920043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06920043, "A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT06920043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*